H.R. 7640 · 117th Congress
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
- Stage
- In committee
- Sponsor
- Gus Bilirakis
- Introduced
- 2022-05-03
- Latest action
- 2022-05-03 · Introduced in House
Summary
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.